Oxigene, Inc.
Oxigene, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Oxigene, Inc..
Oxigene, Inc. is a company.
Key people at Oxigene, Inc..
Key people at Oxigene, Inc..
OXiGENE, Inc. was a clinical-stage biopharmaceutical company focused on developing novel small-molecule therapeutics targeting cancer and eye diseases, with a primary emphasis on vascular targeted therapies (VTT) for orphan oncology indications.[1][2][4][5][7] The company aimed to disrupt tumor blood supply and treat conditions like wet age-related macular degeneration through drugs such as CA4P (fosbretabulin), which received FDA Fast Track designation.[5][8] It served patients with hard-to-treat cancers and retinal disorders but ceased UK operations in 2013, marking the end of its active phase as a development-stage biotech.[3]
Incorporated in the United States under Delaware law (registration 2303211), OXiGENE operated as a public company limited by shares, establishing its first UK presence in 2005 at 230 Third Avenue, Waltham, MA.[3] The company emerged in the early 2000s as a biotech innovator in vascular disrupting agents, building on research into small-molecule compounds to target tumor vasculature.[5][6] Key leadership included executives like Dr. Sherris, who served as COO and VP of R&D, bringing experience from Serono, Centocor, and Unilever Research before advancing OXiGENE's pipeline.[9] Early traction came from clinical advancements, including FDA Fast Track status for CA4P in oncology trials, though it remained pre-commercial.[8]
OXiGENE rode the early 2000s wave of angiogenesis and vascular disruption research in biotech, capitalizing on market forces like rising cancer incidence and demand for targeted therapies over broad cytotoxics.[5][7] Its timing aligned with FDA incentives for orphan drugs and Fast Track programs, influencing the ecosystem by validating VTT as a viable oncology approach—later echoed in approved vascular endothelial growth factor inhibitors for eye diseases.[8] Though it closed its UK arm in 2013 amid biotech funding challenges, its work contributed to foundational science now advanced by successors in retinal and oncology pipelines.[3][9]
As a defunct entity post-2013, OXiGENE's legacy endures through its VTT innovations, with alumni like Dr. Sherris advancing similar tech at firms like Diffusion Pharmaceuticals and Penrose TherapeuTx.[9] Evolving trends in precision oncology and retinal gene therapies may revive its concepts, but without active operations, its direct influence has shifted to historical precedent. Investors eyeing biotech should note how OXiGENE exemplified high-risk pipeline bets that fuel broader ecosystem progress, tying back to its core mission of vascular breakthroughs in unmet diseases.[1][7]
